Bamlanivimab, an antibody effective in treating mild to moderate COVID-19 cases in adults and pediatric patients over 12 years of age who are at a high risk of hospitalization, was released today (11/10) by Ab-Cellera. Following their Phase 2 clinical trial, BLAZE-1, the privately-owned tech company agreed to provide 300,000 doses to the U.S government. The monoclonal antibody therapy Bamlanivimab was procured from the blood of a recovered COVID-19 patient, and many more clinical trials are occurring testing its efficacy.
Read more here.
More on: News Regulatory